The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only therapy available in the United States for suprachoroidal use in the treatment of macular edema associated with uveitis.
Bausch + Lomb Corp. announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has issued a permanent, product specific J-Code J3299 for triamcinolone acetonide injectable suspension (Xipere)
According to a news release, the code will become effective for provider billing on July 1, 2022. J-Codes are reimbursement codes used by both commercial insurers and government payers to quickly identify therapies that are administered by a health care professional incident to the office visit.
“At Bausch + Lomb we are committed to bringing new and innovative therapies to market that benefit eye care professionals and the patients they serve. This not only applies to the development of new therapies, but also making these therapies accessible once they become available,” Yolande Barnard, senior vice president and general manager, U.S. Pharmaceuticals, Bausch + Lomb, said in a statement. “The issuance of the permanent J-Code will help facilitate access to Xipere for Americans suffering from macular edema associated with uveitis and help streamline the reimbursement process.”
According to the news release, triamcinolone acetonide injectable suspensionwas approved by the FDA on October 25, 2021, and is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, which is the leading cause of vision loss in people with uveitis, a form of eye inflammation.1,2 It became commercially available in March.